Epitalon vs Epithalon: Are They the Same Compound? Research Clarified

Epitalon and Epithalon are the same tetrapeptide. Naming disambiguation, telomerase activation research, dosing protocols, and longevity stack context clarified.

TL;DR

• Epitalon and Epithalon are the same compound — Ala-Glu-Asp-Gly, a synthetic tetrapeptide
• The name difference is a Romanization inconsistency from Russian scientific literature, not a chemical difference
• Primary research areas: telomerase activation, melatonin/pineal support, HPA axis modulation
• Khavinson studies show telomere elongation in vitro and lifespan extension in animal models
• Standard research dose: 5–10 mcg/day, 10–20 day cycles, subcutaneous or intranasal

Disclaimer: For educational and research purposes only — not medical advice.

A persistent source of confusion in the longevity peptide research space is the apparent existence of two compounds with very similar names: "Epitalon" and "Epithalon." Are they different? Is one better than the other? Do they have distinct mechanisms or dosing requirements? The short answer: no. They are identical compounds, and the naming discrepancy is purely a transliteration artifact from Russian scientific literature.

This article disambiguates the naming issue, summarizes the research on this compound's mechanisms (particularly telomerase activation), outlines the dosing protocols used in the available studies, and places it in context within longevity-focused peptide research stacks.

The Naming Problem: Epitalon vs. Epithalon

The compound in question is a synthetic tetrapeptide with the amino acid sequence Ala-Glu-Asp-Gly (alanine — glutamic acid — aspartic acid — glycine). In Russian scientific literature, it is written as «Эпиталон» (Epitalon). When transliterated to Latin characters, this Russian word can be rendered either as "Epitalon" or "Epithalon" depending on the transliteration convention used — specifically whether the Russian letter "л" (el) at the end of «эпитал-» is followed by the "on" suffix with or without an "h."

This is entirely analogous to how other Russian scientific terms produce variant spellings in English literature. Neither spelling implies a different compound, formulation, purity standard, or mechanism. Both refer to the same tetrapeptide derived from the work of Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology.

Why does this matter practically? When sourcing or researching this compound, both search terms will appear in vendor catalogs and literature. A product labeled "Epithalon 10 mg" and one labeled "Epitalon 10 mg" are the same compound if the amino acid sequence is Ala-Glu-Asp-Gly. The structure should be confirmable by mass spectrometry or HPLC analysis from any reputable research chemical supplier.

The compound also appears in literature under its chemical description: tetrapeptide Ala-Glu-Asp-Gly, or as Epithalamine-related tetrapeptide (referencing its derivation from epithalamin, the natural pineal extract from which it was synthesized).

Research Background: Origins and Derivation

Epitalon is a synthetic analog of epithalamin — a natural polypeptide extract from bovine pineal glands that was studied extensively by Khavinson's group beginning in the 1970s as part of Soviet biogerontology research. Epithalamin showed biological activity in aging models but was complex to characterize and standardize. Khavinson's group isolated the active tetrapeptide sequence responsible for epithalamin's primary biological effects and synthesized it as Epitalon, allowing for precise dosing and reproducibility.

The primary biological activities attributed to epithalamin — and subsequently studied for Epitalon specifically — include:

• Activation of telomerase in somatic cells
• Stimulation of melatonin production in pineal gland cells (pinealocytes)
• Modulation of HPA axis activity, particularly normalization of elevated cortisol in aging subjects
• Regulation of gonadotropin secretion (FSH, LH)
• Antioxidant effects in multiple tissue models

Khavinson's research program on Epitalon spans more than four decades and includes in vitro, animal, and limited human studies — representing one of the most extensive single-laboratory research programs on any longevity peptide.

Telomerase Activation: The Central Research Finding

The most scientifically significant claim for Epitalon is telomerase activation. Telomeres — the protective caps at chromosome ends — shorten with each cell division. When telomeres reach a critically short length, cells enter replicative senescence (inability to divide) or apoptosis. Telomerase is the enzyme that can elongate telomeres, but it is largely inactive in adult somatic cells (though active in stem cells and cancer cells).

Key studies:

Khavinson et al. (2003, Bulletin of Experimental Biology and Medicine): Demonstrated that Epitalon treatment of human fetal fibroblast cultures activated telomerase expression and elongated telomeres, allowing cells to exceed the Hayflick limit (the normal maximum number of divisions) by 6–10 additional cell divisions compared to controls. This study also noted that treated cells did not show malignant transformation markers, distinguishing the effect from cancerous immortalization.

Khavinson et al. (2004, Neuro Endocrinology Letters): In aging mice, Epitalon treatment at 0.1 mg/kg for 5 days extended mean lifespan by 10.9% compared to controls and reduced age-related pathology markers including tumor incidence.

Anisimov et al. (2006, Bulletin of Experimental Biology and Medicine): Epitalon extended lifespan in female mice with high spontaneous tumor incidence. Treated mice showed reduced tumor frequency and later tumor onset compared to controls.

Fruit fly lifespan data: Multiple studies in Drosophila melanogaster models have shown lifespan extension with Epitalon peptide treatment, consistent with telomere-independent longevity mechanisms (fruit flies have different telomere biology than mammals).

Important caveat: The vast majority of Epitalon telomerase research originates from Khavinson's research group. Independent replication from Western laboratories is limited. The in vitro telomere elongation data in human fibroblasts is the most-cited finding, but its translation to in vivo telomere dynamics in adult humans has not been confirmed in RCTs.

Dosing, Cycling, and Administration Routes

Subcutaneous injection: The most studied route in Khavinson's animal and clinical research. Typical doses in human research contexts: 5–10 mcg/day. Some protocols use 10 mcg/day for a 10-day cycle.

Intranasal administration: Epitalon can be administered intranasally for direct CNS-adjacent delivery. This route is commonly used for the convenience-focused aspect of pineal/melatonin effects. Typical intranasal dose: 10–20 mcg per nostril.

Cycling protocol:

Use the reconstitution calculator to calculate the bacteriostatic water volume needed for your target mcg-per-injection concentration. At 10 mcg/day dosing with a 1 mL total volume, for example, you would need to reconstitute to achieve 10 mcg per injection volume that fits a standard insulin syringe.

Longevity Stack Context

Epitalon is frequently combined with other longevity-focused compounds in research contexts because its mechanisms — telomerase activation and pineal function support — address specific hallmarks of aging that are not covered by NAD+ precursors or mitochondrial support compounds.

A longevity-focused research stack including Epitalon might include:

• NMN or NR (500 mg/day): NAD+ repletion for sirtuin and DNA repair enzyme function
• MOTS-c (5–10 mg twice weekly): AMPK activation, mitochondrial resilience, metabolic function
• Epitalon (5–10 mcg/day, cycled): Telomerase activation, melatonin support, HPA normalization
• Thymalin or Thymosin Alpha-1: Immune system restoration (thymic peptides address immune senescence)

See the full Epitalon research database entry for the complete study summary and citation list.

Regulatory Status

Epitalon is not approved as a pharmaceutical in the United States, European Union, or United Kingdom. It is not listed as a controlled substance under US federal scheduling, nor under analogous EU or UK narcotics frameworks. It is commercially available as a research chemical from peptide synthesis suppliers. Regulatory status can change, and country-specific regulations vary — researchers should verify current status in their jurisdiction before procurement.

Frequently Asked Questions

Q: Is Epitalon safe based on the available research? A: In published Khavinson group studies, Epitalon has not demonstrated significant adverse effects at the doses studied (0.1–1 mg/kg in animals; 5–10 mcg/day in human contexts). No carcinogenic, mutagenic, or teratogenic findings have been reported. The major limitation of the safety database is that most data comes from a single research group, and independent long-term human safety trials are absent. Given the research-chemical status, risk acceptance in research contexts should be made with this limitation in mind.

Q: How do I reconstitute Epitalon for injection? A: Epitalon powder is typically reconstituted with bacteriostatic water (0.9% benzyl alcohol in water for injection). Given the very low per-dose mass (5–10 mcg), accurate reconstitution requires careful volume calculation. Use the reconstitution calculator — for example, adding 1 mL bacteriostatic water to a 1 mg (1,000 mcg) vial gives a concentration of 1,000 mcg/mL, meaning a 5 mcg dose is 0.005 mL (5 µL) — an impractically small injection. Most researchers dilute to 100 mcg/mL (allowing 50–100 µL injections per 5–10 mcg dose) using a larger bacteriostatic water volume.

Q: Can Epitalon increase cancer risk through telomerase activation? A: This is a legitimate mechanistic concern worth addressing. Telomerase is active in ~85% of cancers and contributes to tumor immortality. However, Epitalon activates telomerase in the context of organized somatic cells, not in the uncontrolled proliferative environment of cancer. The Khavinson 2003 fibroblast study specifically examined this — cells treated with Epitalon that exceeded the Hayflick limit did not show oncogenic transformation markers. Additionally, reduced tumor incidence was observed in long-term animal studies with Epitalon treatment. The net cancer risk from research-dose Epitalon in healthy subjects is not established, but the available data does not support concern about cancer induction.

Q: How does Epitalon compare to exogenous melatonin for sleep? A: Epitalon's sleep benefit is indirect — it supports the pineal gland's own melatonin synthesis capacity rather than supplying exogenous melatonin. This is a meaningful distinction for aging subjects where pineal function has declined: restoring endogenous production preserves the pulsatile, circadian-entrained melatonin rhythm that exogenous supplementation imperfectly mimics. For acute sleep onset support, exogenous melatonin at 0.5 mg is more immediately effective. For long-term circadian rhythm restoration, Epitalon's mechanism is more physiologically aligned.

Longevity Research Resources → Epitalon Full Research Database → Reconstitution Calculator → NAD+ Precursors & Longevity Stack Guide

For educational and research purposes only. Not medical advice.

Disclaimer: For educational and research purposes only. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendation. All compounds discussed are research chemicals or investigational compounds unless explicitly noted otherwise. Consult a qualified healthcare professional before making any health-related decisions. Researchers must comply with all applicable laws and regulations in their jurisdiction.

Frequently Asked Questions